Baker BROS. Advisors LP Invests $74.36 Million in Abivax SA Sponsored ADR $ABVX

Baker BROS. Advisors LP bought a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 875,796 shares of the company’s stock, valued at approximately $74,355,000. Abivax accounts for 0.5% of Baker BROS. Advisors LP’s holdings, making the stock its 24th largest holding. Baker BROS. Advisors LP owned 1.13% of Abivax at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ABVX. UBS Group AG boosted its holdings in Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares in the last quarter. Octagon Capital Advisors LP increased its holdings in shares of Abivax by 3.0% during the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after acquiring an additional 37,000 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after acquiring an additional 56,235 shares in the last quarter. Boothbay Fund Management LLC raised its position in shares of Abivax by 52.5% during the second quarter. Boothbay Fund Management LLC now owns 870,438 shares of the company’s stock worth $6,659,000 after purchasing an additional 299,770 shares during the period. Finally, Aberdeen Group plc raised its position in shares of Abivax by 10.8% during the third quarter. Aberdeen Group plc now owns 787,417 shares of the company’s stock worth $66,852,000 after purchasing an additional 76,901 shares during the period. 47.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ABVX. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Morgan Stanley upped their price objective on shares of Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Abivax in a research note on Wednesday, February 25th. Oppenheimer set a $131.00 price objective on shares of Abivax in a report on Thursday, January 8th. Finally, Citigroup reissued a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $134.75.

Abivax Trading Down 1.3%

NASDAQ ABVX opened at $115.50 on Friday. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $118.99 and a 200 day simple moving average of $108.89. Abivax SA Sponsored ADR has a 12 month low of $4.77 and a 12 month high of $148.83. The firm has a market capitalization of $9.13 billion, a P/E ratio of -27.63 and a beta of 1.00.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million for the quarter. On average, analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.